Shanghai Junshi Biosciences Co., Ltd. Class H (HK:1877) has released an update.
Shanghai Junshi Biosciences Co., Ltd. has announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use has issued a positive opinion for the marketing authorization of their drug toripalimab. This sets the stage for potential approval in the European Union for its use as a first-line treatment for certain types of nasopharyngeal and esophageal cancers. The drug, already approved in China and included in the National Reimbursement Drug List, has shown promise in multiple clinical studies.
For further insights into HK:1877 stock, check out TipRanks’ Stock Analysis page.
